3T opthalmics announced that it has completed preliminary pre-clinical testing and is developing protocols for phase 1/2 human clinical trials which are going to begin over the next year for a new drug delivery device. The device is designed to revolutionize the delivery of medication to treat retinal and vitreous conditions. The episcleral drug reservoir is a tiny silicone cup filled with a drug and sealed to the episclera. The device targets the specific part and delivers the drug.
The device is placed under the conjunctiva and attached to the sclera. The cup gradually diffuses the drug through the sclera and to the retina and vitreous, just like an organ-specific transdermal skin patch.